Retina

World's Most Influential People in Ophthalmology

Retrieved on: 
torsdag, maj 9, 2024
Education, FDA, Bascom Palmer Eye Institute, Genetics, Teaching, Surgeon, Paratriathlon, Neuro-ophthalmology, Leach, Strabismus, Cataract, Knowledge, Bascom H. Palmer, Gedde, Eye, DRS, Retina, Vision science, Quality of life, Publication, Research, Bevacizumab, Artificial intelligence, Suture, Health, M.A, Choroideremia, Medeiros, Vance DeGeneres, University, Retinitis pigmentosa, Epidemiology, American Journal, Power, Patient, Physician, Uveitis, Glaucoma, Nursing

MIAMI, May 9, 2024 /PRNewswire/ -- Fifteen Bascom Palmer Eye Institute physicians were selected for the 2024 Power List, a prestigious selection of the world's 100 most influential people shaping the future of eye care, as published by The Ophthalmologist magazine. Drs. Eduardo C. Alfonso, Kendall Donaldson, Hilda Capó, Janet Davis, Harry Flynn, Anat Galor, Steven Gedde, Ranya Habash, Carol Karp, Jaclyn Kovach, Byron Lam, Felipe Medeiros, Richard Parrish, Philip Rosenfeld, and Sonia Yoo were named to the 2024 Power List. Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.

Key Points: 
  • Bascom Palmer Eye Institute is the Department of Ophthalmology for the University of Miami Miller School of Medicine and UHealth – University of Miami Health System.
  • From cutting-edge treatments to groundbreaking research, these doctors are pushing boundaries and setting new standards in ophthalmology."
  • Alfonso, the holder of the Kathleen and Stanley J. Glaser Chair in Ophthalmology, was also named to the Ophthalmologist Power Lists 2014, 2016, 2018, 2022, and 2023.
  • Holder of the John T. Flynn Chair in Ophthalmology, Hilda Capó, M.D., specializes in pediatric ophthalmology and adult strabismus.

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
torsdag, maj 9, 2024
FDA, Regenerative medicine, Research, Choroideremia, Biopsy, European Medicines Agency, Injection, Overalls, Inflammation, Food, Alpha-1 antitrypsin, Cystic fibrosis, Chelsea Handler, Intravitreal administration, Conference, Retina, Atypical hemolytic uremic syndrome, DME, Angiogenesis, PRISM, AMD, Safety, Security (finance), Cash, Retinitis pigmentosa, Exercise, PRIME, EMA, NHP, Clinical trial, A1AT, ASRS, ARVO, ECFS, Șaeș, Cubic foot, Patient, Society, Geographic atrophy, Pharmaceutical industry

“The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Key Points: 
  • “The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • R&D Expenses: Research and development expenses were $27.9 million for the first quarter of 2024, as compared to $22.4 million for the first quarter of 2023.
  • G&A Expenses: General and administrative expenses were $10.3 million for the first quarter of 2024, as compared to $8.0 million for the first quarter of 2023.
  • Net Loss: Net loss was $32.4 million for the first quarter of 2024, as compared to net loss of $28.7 million for the first quarter of 2023.

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

Retrieved on: 
torsdag, maj 9, 2024
Outlook, Retina, Therapy, Conference, Bevacizumab, Pharmaceutical industry

Outlook Therapeutics management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET that same day.

Key Points: 
  • Outlook Therapeutics management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET that same day.
  • The call will be led by Russell Trenary, President and Chief Executive Officer and Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics.
  • Interested participants and investors may access the conference call by dialing (877) 407-8291 (domestic) or (201) 689-8345 (international) and referencing the Outlook Therapeutics Conference Call.
  • The live webcast will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com , and will be archived for 90 days.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Retrieved on: 
onsdag, maj 8, 2024
Respiratory Research, Telecanthus, Liver disease, Boehringer Ingelheim, Publication, Research, Partnership, Development, Administration, ARVO, Therapy, Pulmonary fibrosis, Retina, Patient, Liver, Eye, Fibrosis, Regeneration, SWAP

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2024 financial results and business updates.

Key Points: 
  • Financial Results for the First Quarter Ended March 31, 2024
    Cash Position: Cash and cash equivalents were $27.3 million as of March 31, 2024, compared to $36.0 million as of December 31, 2023.
  • However, inclusive of proceeds from a financing completed in April 2024, the proforma cash for March 31, 2024 would be $43.2M.
  • Restructuring: Restructuring charges for the first quarter ended March 31, 2024 were zero, as compared to $1.2 million for the same period in 2023.
  • Net Loss: Net loss for the first quarter ended March 31, 2024 was $8.8 million, as compared to $14.3 million for the same period in 2023.

Iridex to Report First Quarter 2024 Financial Results on May 14, 2024

Retrieved on: 
onsdag, maj 8, 2024
Glaucoma, Retina, IRIX

MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 14, 2024.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter 2024 after the close of trading on Tuesday, May 14, 2024.
  • The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m.
  • ET.
  • Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com .

Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol

Retrieved on: 
onsdag, maj 8, 2024
UCLA, Stargardt disease, Stargardt, Research, Paratriathlon, Genetics, Retina, Patient, Human genetics, The central science, ABCA4, Clinical trial, Annual general meeting, ARVO, Vitamin A, Pharmaceutical industry

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced the presentation of positive interim data from its TEASE-3 study demonstrating that early-stage Stargardt disease patients treated with gildeuretinol acetate showed no disease progression and remained asymptomatic for the duration of therapy ranging between two and six years.

Key Points: 
  • CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced the presentation of positive interim data from its TEASE-3 study demonstrating that early-stage Stargardt disease patients treated with gildeuretinol acetate showed no disease progression and remained asymptomatic for the duration of therapy ranging between two and six years.
  • Results were presented during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9 in Seattle.
  • “These exciting results demonstrate the potential of gildeuretinol acetate to prevent vision loss in early-stage Stargardt patients,” said Leonide Saad, Ph.D., President and CEO of Alkeus Pharmaceuticals.
  • All of us working in our growing Alkeus team are committed to advancing research and having an impact on patients living with vision loss.

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

Retrieved on: 
onsdag, maj 8, 2024
Therapy, Retina, SAN

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2024.

Key Points: 
  • SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2024.
  • You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events .
  • A replay will be available for approximately 90 days after the event.

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Retrieved on: 
onsdag, maj 8, 2024
Dexamethasone, Pain, State, Inflammation, Investment, Refractive surgery, Safety, NDA, OCS, Research, Cataract, DED, AON, Development, IND, Retina, ASCRS, Research and development, Patient, Society, Pharming, CHF, Genotype, DME, Bank statement, Clinical trial, Annual general meeting, Ophthalmology, Pharmaceutical industry

The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.

Key Points: 
  • The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.
  • Concurrently, the Company listed on the Nasdaq Iceland Main Market in addition to Nasdaq Global Market in the U.S.
    Snehal Shah, Pharm.
  • The Company also aims to complete an IND submission for OCS-05 in the U.S. in 2024.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Retrieved on: 
måndag, maj 6, 2024
Stargardt disease, MB BS, Geographic atrophy, FACS, Royal College of Ophthalmologists, MB, Therapy, Retina, Bachelor of Science, Eye, Research fellow, Macular degeneration, RBP4, Moorfields Eye Hospital, ARVO

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a Key Opinion Leader Webinar hosted by Jennifer Kim, Director, Equity Research, of Cantor Fitzgerald on Monday, May 13, 2024, at 2:00 p.m. ET.

Key Points: 
  • Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m.
  • The event will feature Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS (University College London Institute of Ophthalmology and Moorfields Eye Hospital), who will discuss an overview of the unmet need for treatments in Stargardt disease (STGD1) and Geographic Atrophy (GA).
  • Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1.
  • A replay of the webinar will be available approximately one week after the event for 90 days under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events .

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Retrieved on: 
måndag, maj 6, 2024
Stargardt disease, University, Bias, Westmead, Stargardt, Research, Geographic atrophy, DRAGON, Adolescence, Growth, Observation, Disease, Therapy, Retina, Dry, Patient, Classification, CSO, Genotype, ABCA4, Annual general meeting, Belite, ARVO, SAN, Visual acuity, Pharmaceutical industry

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with STGD1 and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD).

Key Points: 
  • Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with STGD1 and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD).
  • Genetic profiling was performed on the 13 adolescent STGD1 patients enrolled in a Phase 2 study of Tinlarebant.
  • “Data from the genotype and lesion growth analyses from our completed Phase 2 trial continues to demonstrate the efficacy of Tinlarebant,” said Dr. Nathan Mata, CSO of Belite Bio.
  • The presentation is now available in the “Presentations & Events” section of Belite Bio’s website: https://investors.belitebio.com/presentations-events/events.